...
search icon
kynb-img

Kyntra Bio, Inc. Share Price

KYNB
NSQ
$7.33
-$0.12
(-1.61%)
1D

Kyntra Bio, Inc. Analyst Forecast

Kyntra Bio, Inc. Share Price Chart

Kyntra Bio, Inc. Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$30.14M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
44.15K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.85 L
$21.95 H
$7.33

About Kyntra Bio, Inc., Common Stock

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. more

Kyntra Bio, Inc. Stock Returns

Data is not properly formatted.

Kyntra Bio, Inc. Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue176.32M235.31M140.73M46.80M29.62M[{"date":"2020-12-31","value":74.93,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":59.81,"profit":true},{"date":"2023-12-31","value":19.89,"profit":true},{"date":"2024-12-31","value":12.59,"profit":true}]
Cost of Revenue8.87M449.19M20.28M3.96M15.56M[{"date":"2020-12-31","value":1.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.51,"profit":true},{"date":"2023-12-31","value":0.88,"profit":true},{"date":"2024-12-31","value":3.46,"profit":true}]
Gross Profit167.45M(213.88M)120.45M42.84M14.06M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-127.73,"profit":false},{"date":"2022-12-31","value":71.93,"profit":true},{"date":"2023-12-31","value":25.58,"profit":true},{"date":"2024-12-31","value":8.4,"profit":true}]
Gross Margin94.97%(90.89%)85.59%91.53%47.47%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-95.71,"profit":false},{"date":"2022-12-31","value":90.12,"profit":true},{"date":"2023-12-31","value":96.38,"profit":true},{"date":"2024-12-31","value":49.98,"profit":true}]
Operating Expenses359.33M74.65M421.48M365.56M164.48M[{"date":"2020-12-31","value":85.25,"profit":true},{"date":"2021-12-31","value":17.71,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.73,"profit":true},{"date":"2024-12-31","value":39.02,"profit":true}]
Operating Income(191.88M)(288.53M)(301.02M)(322.72M)(150.42M)[{"date":"2020-12-31","value":-19188000000,"profit":false},{"date":"2021-12-31","value":-28853000000,"profit":false},{"date":"2022-12-31","value":-30102500000,"profit":false},{"date":"2023-12-31","value":-32272100000,"profit":false},{"date":"2024-12-31","value":-15041600000,"profit":false}]
Total Non-Operating Income/Expense-(3.30M)13.88M(1.00M)(5.90M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-23.76,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-7.22,"profit":false},{"date":"2024-12-31","value":-42.51,"profit":false}]
Pre-Tax Income(188.93M)(289.68M)(293.30M)(323.22M)(153.37M)[{"date":"2020-12-31","value":-18893100000,"profit":false},{"date":"2021-12-31","value":-28967600000,"profit":false},{"date":"2022-12-31","value":-29329600000,"profit":false},{"date":"2023-12-31","value":-32322200000,"profit":false},{"date":"2024-12-31","value":-15336700000,"profit":false}]
Income Taxes360.00K347.00K358.00K(252.00K)(269.00K)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.39,"profit":true},{"date":"2022-12-31","value":99.44,"profit":true},{"date":"2023-12-31","value":-70,"profit":false},{"date":"2024-12-31","value":-74.72,"profit":false}]
Income After Taxes-(290.02M)(293.65M)(322.97M)(153.10M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-29002300000,"profit":false},{"date":"2022-12-31","value":-29365400000,"profit":false},{"date":"2023-12-31","value":-32297000000,"profit":false},{"date":"2024-12-31","value":-15309800000,"profit":false}]
Income From Continuous Operations-(290.02M)(293.65M)(322.97M)(153.10M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-29002300000,"profit":false},{"date":"2022-12-31","value":-29365400000,"profit":false},{"date":"2023-12-31","value":-32297000000,"profit":false},{"date":"2024-12-31","value":-15309800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(189.29M)(290.02M)(293.65M)(284.23M)(47.58M)[{"date":"2020-12-31","value":-18929100000,"profit":false},{"date":"2021-12-31","value":-29002300000,"profit":false},{"date":"2022-12-31","value":-29365400000,"profit":false},{"date":"2023-12-31","value":-28423200000,"profit":false},{"date":"2024-12-31","value":-4757900000,"profit":false}]
EPS (Diluted)(2.13)(3.14)(3.14)(2.93)(0.48)[{"date":"2020-12-31","value":-213,"profit":false},{"date":"2021-12-31","value":-314,"profit":false},{"date":"2022-12-31","value":-314,"profit":false},{"date":"2023-12-31","value":-293,"profit":false},{"date":"2024-12-31","value":-48,"profit":false}]

Kyntra Bio, Inc. Ratios

Kyntra Bio, Inc. Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

KYNB
Cash Ratio 3.28
Current Ratio 3.71
Quick Ratio 3.60

Kyntra Bio, Inc. Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KYNB
ROA (LTM) -18.42%
ROE (LTM) 0.00%

Kyntra Bio, Inc. Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KYNB
Debt Ratio Lower is generally better. Negative is bad. 0.87
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.12

Kyntra Bio, Inc. Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KYNB
Trailing PE NM
Forward PE 61.35
P/S (TTM) 3.63
P/B 0.00
Price/FCF NM
EV/R 9.73
EV/Ebitda NM

FAQs

What is Kyntra Bio, Inc. share price today?

Kyntra Bio, Inc. (KYNB) share price today is $7.33

Can Indians buy Kyntra Bio, Inc. shares?

Yes, Indians can buy shares of Kyntra Bio, Inc. (KYNB) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KYNB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kyntra Bio, Inc. be purchased?

Yes, you can purchase fractional shares of Kyntra Bio, Inc. (KYNB) via the Vested app. You can start investing in Kyntra Bio, Inc. (KYNB) with a minimum investment of $1.

How to invest in Kyntra Bio, Inc. shares from India?

You can invest in shares of Kyntra Bio, Inc. (KYNB) via Vested in three simple steps:

  • Click on Sign Up or Invest in KYNB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kyntra Bio, Inc. shares
What is Kyntra Bio, Inc. 52-week high and low stock price?

The 52-week high price of Kyntra Bio, Inc. (KYNB) is $21.95. The 52-week low price of Kyntra Bio, Inc. (KYNB) is $4.85.

What is Kyntra Bio, Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kyntra Bio, Inc. (KYNB) is

What is Kyntra Bio, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kyntra Bio, Inc. (KYNB) is 0.00

What is Kyntra Bio, Inc. dividend yield?

The dividend yield of Kyntra Bio, Inc. (KYNB) is 0.00%

What is the Market Cap of Kyntra Bio, Inc.?

The market capitalization of Kyntra Bio, Inc. (KYNB) is $30.14M

What is Kyntra Bio, Inc.'s stock symbol?

The stock symbol (or ticker) of Kyntra Bio, Inc. is KYNB

How Can Investors Use Kyntra Bio, Inc. Share Price Data for Long-Term Investment Decisions?

Consider the share price of Kyntra Bio, Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Kyntra Bio, Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Kyntra Bio, Inc. shares for Indian investors?

When investing in Kyntra Bio, Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Kyntra Bio, Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Kyntra Bio, Inc. share price with other stocks in the same sector?

Rather than merely checking the share price of Kyntra Bio, Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Kyntra Bio, Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top